Scarica l'app Stockscreener
5.825
6.05%
-0.375
Dopo l'orario di chiusura:
5.82
-0.005
-0.09%
Precedente Chiudi:
$6.20
Aprire:
$6.02
Volume 24 ore:
729.47K
Relative Volume:
0.64
Capitalizzazione di mercato:
$312.15M
Reddito:
-
Utile/perdita netta:
$-52.90M
Rapporto P/E:
-4.0359
EPS:
-1.4433
Flusso di cassa netto:
$-48.79M
1 W Prestazione:
+0.95%
1M Prestazione:
-10.38%
6M Prestazione:
+84.92%
1 anno Prestazione:
+60.47%
Intervallo 1D:
$5.81
$6.15
Intervallo di 1 settimana:
$5.645
$6.56
Portata 52W:
$2.77
$7.82
Protara Therapeutics Inc Stock (TARA) Company Profile
Nome
Protara Therapeutics Inc
Settore
Industria
Telefono
646-844-0337
Indirizzo
345 PARK AVENUE SOUTH, NEW YORK, NY
Compare TARA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
5.825 | 332.24M | 0 | -52.90M | -48.79M | -1.4433 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Iniziato | Piper Sandler | Overweight |
| 2025-04-16 | Iniziato | Scotiabank | Sector Outperform |
| 2025-03-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-07-10 | Ripresa | Guggenheim | Buy |
| 2021-06-04 | Iniziato | H.C. Wainwright | Buy |
| 2021-02-17 | Iniziato | Oppenheimer | Outperform |
| 2020-10-19 | Iniziato | Cowen | Outperform |
| 2020-07-29 | Iniziato | Guggenheim | Buy |
Mostra tutto
Protara Therapeutics Inc Borsa (TARA) Ultime notizie
Protara gains as JP Morgan starts at overweight - Seeking Alpha
Protara Therapeutics (NASDAQ:TARA) Now Covered by JPMorgan Chase & Co. - MarketBeat
JP Morgan Initiates Coverage on TARA with Overweight Rating and $27 PT | TARA Stock News - GuruFocus
Breakout Watch: Can Protara Therapeutics Inc beat the S P 5002025 Sector Review & Weekly High Return Opportunities - baoquankhu1.vn
Millennium group reports 2.76M shares in Protara (TARA) — 5.1% stake - Stock Titan
Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer Conf - Yahoo Finance
TARA PE Ratio & Valuation, Is TARA Overvalued - Intellectia AI
TARA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Protara Therapeutics Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
TARA Should I Buy - Intellectia AI
Protara Therapeutics, Inc. (TARA) Presents at 2026 ASCO Genitourinary Cancers SymposiumSlideshow - Seeking Alpha
TARA: TARA-002 advances in NMIBC and LM with promising data and expanding regulatory pathways - TradingView
667, L.P. resale reported for TARA (NASDAQ: TARA) — 26,755 shares - Stock Titan
Protara Therapeutics (TARA) Receives a Buy from Piper Sandler - The Globe and Mail
Protara Therapeutics (TARA) to Release Earnings on Wednesday - MarketBeat
Protara Therapeutics Highlights Phase 2 TARA-002 Data in NMIBC, Cites Strong Response Rates at ASCO GU - MarketBeat
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), Protara Therapeutics (TARA) and Kiniksa Pharmaceuticals (KNSA) - The Globe and Mail
Protara Therapeutics (TARA) Shares Drop 22% After Interim Trial Data - GuruFocus
[144] Protara Therapeutics, Inc. SEC Filing - Stock Titan
Protara reports interim results from bladder cancer trial By Investing.com - Investing.com South Africa
Protara falls after trial data for lead asset (TARA:NASDAQ) - Seeking Alpha
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Bladder phase II sinks Protara, LMs phase III wins for Palvella - bioworld.com
Protara Highlights Strong Phase 2 Data for TARA-002 - TipRanks
TARA: TARA-002 shows strong efficacy and safety in NMIBC, with high CR rates and durable responses - TradingView
Protara posts positive interim ADVANCED-2 results; TARA-002 shows 68% 6‑month CR in BCG‑unresponsive NMIBC - TradingView
What's Going On With Protara Therapeutics Stock Tuesday?Protara Therapeutics (NASDAQ:TARA) - Benzinga
TARA-002 results send Protara shares upwards - The Pharma Letter
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Does TARA Stock’s 15% After-Hours Slump Signal A Bargain After New Bladder Cancer Data? - Stocktwits
Protara Therapeutics stock tumbles on trial data release By Investing.com - Investing.com South Africa
Protara Therapeutics (TARA) Shares Promising Phase 2 Trial Resul - GuruFocus
Protara Therapeutics stock tumbles on trial data release - Investing.com
Protara Therapeutics (TARA) Shares Promising Phase 2 Trial Results - GuruFocus
Protara reports interim results from bladder cancer trial - Investing.com
TARA-002 demonstrates 68% complete response rate at six months in BCG-unresponsive non-muscle invasive bladder cancer - marketscreener.com
TARA-002 Demonstrates 68% Complete Response Rate at Six - GlobeNewswire
Protara's Experimental Bladder Cancer Drug Shows Encouraging Results - Bitget
Piper Sandler Reaffirms Their Buy Rating on Protara Therapeutics (TARA) - The Globe and Mail
Should I average down on Protara Therapeutics Inc. stockBuy Signal & Fast Exit Strategy with Risk Control - mfd.ru
Protara Therapeutics to Participate in Upcoming Investor Conferences - Bitget
Muscle Invasive Bladder Cancer Market: Pharma Pipeline Fuels Rapid Expansion by 2034 – DelveInsight | CG Oncology, Pfizer, UroGen Pharma, Janssen R&D, Protara Therapeutics, Binhui Biopharmaceutical - Barchart.com
Published on: 2026-02-19 10:51:48 - baoquankhu1.vn
TARA Technical Analysis & Stock Price Forecast - Intellectia AI
ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards - The Chronicle-Journal
Published on: 2026-02-16 18:05:35 - baoquankhu1.vn
Published on: 2026-02-16 20:21:04 - baoquankhu1.vn
Protara Therapeutics (NASDAQ:TARA) Given Buy Rating at HC Wainwright - Defense World
Protara Therapeutics (TARA): HC Wainwright Reiterates Buy Rating | TARA Stock News - GuruFocus
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Why Protara Therapeutics Inc. stock is seen as undervaluedExit Point & Real-Time Stock Movement Alerts - mfd.ru
Protara Therapeutics Inc Azioni (TARA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.69%
0.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):